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S U M M A R Y
Background: There are no reliable risk factors to accurately predict progression to cervical cancer in
patients with chronic cervicitis infected with human papillomavirus (HPV). The aim of this study was to
create a validated predictive model based on the risk factors for cervical cancer. A model to estimate the
risk of cervical cancer may help select patients for intervention therapy in order to reduce the occurrence
of cervical cancer after HPV infection.
Methods: This retrospective analysis included 68 patients with cervical cancer and 202 healthy female
controls. HPV infection and human leukocyte antigen (HLA) class II alleles in HLA-DRB1, 3–7, and 9 were
detected. Other information was collected, including level of education and age at ﬁrst parturition.
Multiple regression analysis and an artiﬁcial neural network (ANN) were performed to identify the
independent risk factors for cervical cancer, and based on these, an evaluation model for the prediction of
the incidence of cervical cancer was formed.
Results: This model showed HPV to be a pivotal player in cervical cancer that increased the risk by 7.6-
fold. The presence of the HLA-DRB1*13-2 and HLA-DRB1*3(17) alleles was associated with an increased
risk of developing cervical cancer. Conversely, the HLA-DRB1*09012 and HLA-DRB1*1201 alleles were
found to be associated with a reduced cervical cancer risk. In addition, other factors, such as age at ﬁrst
parturition and education level, had signiﬁcant effects on cervical cancer risk. The model was applied to
conduct a risk assessment of women in the mountain area of Wufeng County, Hubei Province in China.
The sensitivity and speciﬁcity of our model both exceeded 95%.
Conclusions: This model, based on etiology and HLA allele susceptibility, can estimate the risk of cervical
cancer in chronic cervicitis patients after HPV infection. It combines genetic and environmental factors
and signiﬁcantly enhances the accuracy of risk evaluation for cervical cancer. This model could be used to
select patients for intervention therapy and to guide patient classiﬁcation management.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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A risk evaluation model is crucial for efﬁcient cancer screening
among high-risk populations.1 Environmental factors, such as
education level, age at sexual debut, parity, and body mass index* Corresponding author. Tel.: +86 27 68758898; fax: +86 27 68758766.
E-mail address: wuxinxing9755@163.com (X. Wu).
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license (http://creativecommons.org/licenses/by-nc-nd/3.0/).(BMI), are related to the risk of developing cervical cancer. Some
genetic factors (e.g., interferon regulatory factor 1 (IRF-1)) in which
speciﬁc polymorphisms correlate with cervical cancer have been
reported.2 Several other genes, such as codon 72 of p53, codon
31 of p21, and fragile histidine triad (FHIT), have been examined
for their association with cervical cancer. Cervical carcinogenesis is
a multifactorial disease that may result from environmental and
genetic factors. To improve the predictive accuracy for determin-
ing the cervical cancer risk, we developed a risk evaluation model
comprising both genetic and environmental factors.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Coding table of variables
Variable Status Coding
HPV high risk (16, 18/45, 52, 58) Negative 0
Positive 1
Genetic factor: HLA-DRB1*09012 +
DRB1*1201 + DRB1*13-2 + DRB1*3(17)
DRB1*09012 Yes 0
No 1
DRB1*1201 Yes 0
No 1
DRB1*13-2 Yes 1
No 0
DRB1*3(17) Yes 1
No 0
Education level coding
in reverse direction
Below primary
school
5
Primary school 4
Junior high school 3
High school 2
College and above 1
HPV, human papillomavirus.
Table 2
Results of multiple regression analysis for cervical cancer risk factors
bi SE (bi) Wald p-Value OR
HPV infection 2.032 0.652 9.703 0.002 7.626
Genetic factor 0.854 0.454 3.544 0.060 2.349
Education level of woman 0.710 0.351 4.096 0.043 2.034
Education level of spouse 1.345 0.367 13.443 0.001 3.837
Age at ﬁrst birth 0.380 0.201 3.575 0.059 0.684
Constant 1.174 4.838 0.059 0.808 -
SE, standard error; OR, odds ratio; HPV, human papillomavirus.
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cervical cancer based on several well-known environmental
contributors, such as infection with high-risk genotype(s) of human
papillomavirus (HPV),3–5 young age at ﬁrst parturition,6 and low
education level of the subject and their spouse.7,8 Emerging evidence
suggests that human leukocyte antigen (HLA) class II alleles are
associated with cervical cancer.9 In this study, we combined HLA
class II alleles with several risk factors to establish a risk evaluation
model using multiple logistic regression analysis and an artiﬁcial
neural network. This new evaluation model could signiﬁcantly
improve the accuracy of risk evaluation for cervical cancer.
2. Materials and methods
2.1. Subjects
Demographic information and blood samples were collected
from 68 patients with cervical cancer and 202 healthy female
controls admitted to the Healthcare Hospital for Women and
Children of Wufeng County in Hubei Province, China between March
2002 and December 2009. All patients were diagnosed with cervical
squamous cell carcinoma based on pathological examination. The
average age of the patients was 51.8  10.0 years (mean  standard
deviation) and ranged from 35 to 75 years. The average age of the
controls was 42.5  8.1 years and ranged from 22 to 73 years. All data
from patients and controls were assigned randomly to one of two
subsets. One subset comprised data from 63 patients and 192 controls
and was used to establish the risk evaluation model. The other subset
included data from ﬁve patients and 10 controls and was used to test
the model. All patients and healthy controls gave written informed
consent for the use of the specimens obtained for medical research. The
study was approved by the ethics committee of the local institution and
the basic medical school of Wuhan University.
2.2. Detection of HPV infection
HPV infection was identiﬁed by the ampliﬁcation of HPV DNA
from cervical cell scrapings, as described previously.10
2.3. Questionnaire and health examination
A questionnaire and health examination were conducted, as
described previously.7
2.4. Genotyping of HLA-II alleles
HLA class II genotypes of the study subjects were determined by
DNA sequencing.10 HLA gene typing was performed for 68 cervical
cancer cases and 202 controls. DNA was extracted by the phenol/
chloroform method using peripheral blood mononuclear cells.
DNA samples were typed at the HLA-DRB1, DRB3, DRB4, DRB5,
DRB6, DRB7, and DRB9 loci using an HLA-DRB gene typing chip
(United Gene, Shanghai, China) with a sequence-speciﬁc oligonu-
cleotide probe (SSOP). Each HLA II allele was ampliﬁed and
hybridized individually using locus-speciﬁc probe arrays. SSOP
reactions for each sample were submitted electronically to an HLA
analysis program to deduce the HLA type. HLA-DR genes were
identiﬁed and named in concordance with the 12th International
Histocompatibility Workshop and Conference.
2.5. Backpropagation
Backpropagation (BP) is a common algorithmic approach by
which an artiﬁcial neural network (ANN) is instructed to perform a
given task.11 The BP algorithm consists of the following two parts:
propagation and weight update. We used the Levenberg–Marquardt method, an optimized BP algorithm with a three-
layered ANN, and nine hidden neurons. The input variables
included environmental risk factors (high-risk HPV infection,
education level of the subject and their spouse, and age at ﬁrst
parturition) and genetic contributors (HLA-DRB1*09012, HLA-
DRB1*1201, HLA-DRB1*13-2, and DRB1*3(17)). The method for
normalization of the input sample is described by the following
equation: x0 = x/max(x).
The initial weighted value of the neural network was gained
from an initiff process. The transfer function between the input and
output layer was a logarithm S-shaped function (logic) and it
between the hidden and output layer was a linear function
(purelin). For other indices, one hidden layer was used. The
independent variables are described in Table 1. The deviation index
(eg) was 0.09 and the maximum training steps (me) was 1000.
3. Results
Based on multiple regression analysis, the risk factors for
cervical cancer included high-risk HPV infection, low education
level of the individual and their spouse, young age at ﬁrst
parturition, HLA class II susceptibility alleles, and non-protective
HLA alleles. Compared with uninfected women, the risk for cervical
cancer in women with high-risk HPV infection increased approxi-
mately 7.6-fold (Table 2). High-risk HLA alleles also increased the
risk of cervical cancer 2.3-fold in women lacking protective HLA
alleles (Table 2). When women and their spouses had a lower level
of education, the risk of cervical cancer increased 2.0- and 3.8-fold,
respectively (Table 2). Backﬁtting indicated that the accuracy of
predicting cervical cancer was 88.9% in the patient group and 98.4%
in the control group (Table 3). The testing database showed that
the accuracy of the risk model was 100% in the cancer group and
reached 90% in the control group (Table 4), suggesting that this
model has good predictive speciﬁcity and sensitivity.
Table 3
Backﬁtting result of the multiple logistic regression model for cervical cancer
classiﬁcationa
Evaluation of model
Cancer
0 1
Clinical data Cancer 0 189 (98.4%) 3
1 7 56 (88.9%)
a The number in brackets is the accuracy of classiﬁcation.
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developed using the BP of an ANN. To test the capacity of this
model to predict and classify unknown data, we applied the model
to the test data using the coding rule listed in Table 2. The ANN
model also demonstrated good classiﬁcation ability. The predictive
results on the test data showed that the accuracy in predicting
cervical cancer was 80% in the patient group and 90% in the control
group (Table 5), and the back substitution ﬁtting had a high
accuracy of classiﬁcation. A sensitivity of 95.2% and a speciﬁcity of
99% were achieved with the ANN model (Table 6). This optimized
model is compatible with input parameters.
4. Discussion
Epidemiological investigations have conﬁrmed that more than
70% of women are infected with HPV, but most infection is
transient. Only a small proportion progress to persistent infection
and then develop cervical cancer.12 A predictive model is urgently
needed to evaluate the cervical cancer-associated risk factors.
Recent studies have demonstrated that the host genetic
background may play a crucial role in the development of cervical
cancer.13 In humans, the major histocompatibility complex is
referred to as the HLA system. This group of genes resides on
chromosome 6 and encodes several proteins, including the HLA
class II histocompatibility antigens, which are essential for the
functions of the human immune system. HLA class II molecules are
expressed on the surface of antigen-presenting cells and consist of
an alpha chain (DRA) and a beta chain (DRB). The most prevalent
beta subunit of HLA-DR is DRB1-9, encoded by the HLA-DRB1 gene,
which plays a central role in the immune system by presenting
peptides derived from extracellular proteins.
Previous reports14–18 have suggested that the risk of cervical
cancer may be associated with speciﬁc HLA alleles or HLA-linked
genes. Several studies have indicated that the cellular immuneTable 4
Predictive results for cervical cancer with the multiple logistic regression evaluation m
Clinical
group
Predictive
group
Predictive
valuea
X1
(HPV
infection)
X2
(Gen
fact
Control Control 1.8 0 1 
Control Control 0.7 0 1 
Control Control 5.0 0 1 
Control Control 6.7 0 1 
Control Control 6.2 0 2 
Control Case 0.4 1 2 
Control Control 8.1 0 1 
Control Control 6.4 0 3 
Control Control 1.8 0 1 
Control Control 6.5 0 2 
Case Case 1.7 0 4 
Case Case 0.8 1 2 
Case Case 0.6 0 1 
Case Case 6.4 1 2 
Case Case 4.1 1 2 
HPV, human papillomavirus.
a If the predictive value is 0, then the predictive group is the control group; if the response is essential for clearance of HPV infection.19,20 Different
combinations of HLA class II molecules and antigenic peptides
may inﬂuence cytokine production during the early stage of the
immune response to HPV infection. The peptide epitopes that are
encoded by HLA susceptibility alleles are unable to present
cervical cancer-derived antigens to T cells, and the cervical cancer
risk may be increased or decreased depending on the HLA class II
alleles.19,21,22 In a previous study we indicated that HLA-A*0206 is
a protective allele against the development of cervical cancer by
presenting HPV16E711-20 and the peptide epitope of E786-93 to
antigen-presenting cells and provoking cytotoxic T lymphocytes
to destroy target cells.3 In this study, we focused on HLA class II
alleles that are associated with the presentation of cancer
antigens.23
Using multiple logistic regression analysis and an ANN we
established a risk evaluation model for cervical cancer. Our data
showed that HPV plays a pivotal role in cervical cancer, as reported
previously, increasing the risk 7.6-fold. The presence of the HLA-
DRB1*13-2 and HLA-DRB1*3(17) alleles was found to be associated
with an increased risk of cervical cancer carcinogenesis. Converse-
ly, the HLA-DRB1*09012 and HLA-DRB1*1201 alleles were found
to be associated with a reduced risk of cervical cancer.10 In
addition, other factors, such as age at birth of ﬁrst child and
education level, had signiﬁcant effects on cervical cancer risk.
The model was applied to conduct a risk assessment of women
in the mountain area of Wufeng County, Hubei Province in China.
The sensitivity and speciﬁcity of this model exceeded 95%. There
were two cases among the cohort of 192 normal cases that the ANN
model judged as high risk and three cases with a clinical diagnosis
of cervical cancer that the model judged as low risk. We considered
that the primary reason for this is related to individual differences
in genetic background. Another reason could be the heavy weight
of high-risk HPV in the model, and we only incorporated common
high-risk HPV types (HPV16, 18, 45, 52, 58) in the model, which
may therefore miss the other HPV type infections. Along with the
improvements in people’s living conditions and healthcare
consciousness, the patient with chronic cervicitis and an HPV
infection could undergo active treatment as an intervention, which
could signiﬁcantly delay or even completely prevent cervical
carcinogenesis.
Our results support the hypothesis that HLA class II DRB alleles
inﬂuence the risk of developing invasive cervical cancer. This
model takes HLA class II alleles as genetic risk factors and the other
risk factors correlated with cervical cancer into consideration,odel on the test data
etic
or)
X3
(Reverse coding
of education
level of woman)
X4
(Reverse coding
of education
level of spouse)
X5
(Age at
ﬁrst birth)
3 3 20
5 3 21
3 2 25
2 1 24
2 1 25
3 3 22
1 1 26
1 1 26
4 3 22
1 1 24
4 4 23
3 3 21
5 4 21
5 5 17
5 5 23
predictive value is >0, then the predictive group is the case group.
Table 5
Predictive results for cervical cancer with the ANN model on the test dataa
Practical
group
Predictive
group
Predictive
valueb
X1
(HPV
infection)
X2
(Reverse coding
of education
level of woman)
X3
(Reverse coding
of education
level of spouse)
X4
(Age at
ﬁrst birth)
X5
(Genetic
factor)
Control Control 0.0000 0 0.6 0.6 0.67 0.25
Control Control 0.0377 0 1 0.6 0.70 0.25
Control Control 0.0000 0 0.6 0.4 0.83 0.25
Control Control 0.0000 0 0.4 0.2 0.80 0.25
Control Control 0.0001 0 0.4 0.2 0.83 0.5
Control Case 1.0000 1 0.6 0.6 0.73 0.5
Control Control 0.0000 0 0.2 0.2 0.87 0.25
Control Control 0.0000 0 0.2 0.2 0.87 0.75
Control Control 0.0000 0 0.8 0.6 0.73 0.25
Control Control 0.0000 0 0.2 0.2 0.80 0.5
Case Case 1.0000 0 0.8 0.8 0.77 1
Case Case 1.2049 1 0.6 0.6 0.70 0.5
Case Control 0.0055 0 1 0.8 0.70 0.25
Case Case 1.0000 1 1 1 0.57 0.5
Case Case 1.0000 1 1 1 0.77 0.5
ANN, artiﬁcial neural network; HPV, human papillomavirus.
a The data in Table 5 are from the testing data, which are the same as the testing data for the logistic regression model, and these were normalized.
b If the predictive value is <0.5, then the predictive group is the control group; if the predictive value is 0.5, then the predictive group is the case group.
Table 6
Back substitution ﬁtting results of the ANN evaluation classiﬁcation modela
Classiﬁcation results
by model
Case
0 1
Clinical data Case 0 190 (99.0%) 2
1 3 60 (95.2%)
a The number in brackets is the accuracy of classiﬁcation.
B. Hu et al. / International Journal of Infectious Diseases 28 (2014) 8–12 11which has not been reported previously; our results showed that
HLA polymorphisms are closely related to genetic susceptibility to
cervical cancer and HPV infection in the Chinese population. In
particular, we found the HLA-DRB1*13-2 and HLA DRB1*3(17)
alleles to be associated with an increased risk of developing
cervical cancer. A better understanding of these associations would
help to elucidate the role that HLA molecules play in the immune
response to HPV infection and subsequent cervical cancer
pathogenesis in the Chinese population. Moreover, this work
may help to improve the current strategies for the prevention and
treatment of cervical cancer through vaccination and immuno-
therapy. The model has theoretical and application value via
screening high-risk HPV infections and monitoring HLA alleles to
predict the risk of cervical cancer. This model could be used to
select patients for intervention therapy (control of cervical erosion,
microwave therapy, frozen treatment, loop electrosurgical exci-
sion procedure (LEEP) knife operation, etc.) and guide patient
classiﬁcation management.
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